Mucolase

Mucolase: A Comprehensive Reference

Important Preliminary Note on Identity and Nomenclature

The term Mucolase exists in more than one distinct context and must be carefully distinguished at the outset. In the dietary supplement literature, Mucolase most prominently refers to a proprietary mucolytic enzyme ingredient developed and trademarked by Enzymedica, Inc., and used as the active component in products such as Enzymedica's MucoStop® formulation. In a separate, older pharmaceutical context—largely outside the United States—the name "Mucolase" has also appeared as a brand designation for preparations containing carbocysteine, a synthetic mucolytic drug. One pharmaceutical manufacturer, Meteoric Biopharmaceuticals, describes a product called Mucolase as a specialty carbocysteine-containing preparation with mucolytic action both in vivo and on human sputum samples. This article focuses primarily on the supplement-industry ingredient—the proteolytic/mucolytic enzyme blend—while cross-referencing the broader mucolytic enzyme science that informs claims made about it.

Identity and Chemical Nature

Proprietary Enzyme Ingredient (Supplement Context)

Mucolase is described by Enzymedica as a high-potency proteolytic enzyme with mucolytic properties, meaning it targets and hydrolyzes excess mucus. It is a mucolytic enzyme used within a multi-enzyme Thera-blend system formulated to work across a range of pH levels. Enzymedica has not publicly disclosed the precise microbial fermentation source, organism of origin, or EC classification number for the specific proprietary Mucolase enzyme, and no peer-reviewed publications isolating or characterizing this specific commercial ingredient by the trade name "Mucolase" appear in the scientific literature. The ingredient is not listed in open enzyme databases by this trade name as of the time of writing, and therefore its detailed biochemical identity—beyond its broad classification as a mucolytic/proteolytic enzyme—cannot be fully characterized from publicly available, peer-reviewed sources.

Mucolase is described in product materials as helping to break down mucoproteins and complex polysaccharides in mucus, making it less viscous and aiding mucus clearance from the airways, supported by additional protease and carbohydrase components.

Substrate: The Nature of Mucus and Mucins

To understand how a mucolytic enzyme like Mucolase is theorized to work, it is essential to understand its substrate—mucus. Mucus is comprised of water, ions, mucin glycoproteins, and a variety of other macromolecules, some of which possess anti-microbial, anti-protease, and anti-oxidant activities. Mucins comprise the major protein component of mucus and exist as secreted and cell-associated glycoproteins.

Structurally, mucins share several key characteristics. All of them have a protein backbone (the "apomucin" core) with a similar composition of domains. In particular, this backbone is enriched with variable-length, tandemly repeating regions of proline-threonine-serine (PTS) domains, where exposed hydroxyl groups on threonine and serine act as potential sites of O-glycosylation. PTS domains are responsible for the bottlebrush-like structure of mucins, where densely grafted glycans are displayed radially outward from the protein core.

The O-glycan structures that are attached to mucins contain N-acetylgalactosamine, N-acetylglucosamine, fucose, galactose, sialic acid, and traces of mannose. These O-glycan structures constitute up to 80% of the total molecular weight of the final mucin glycoprotein.

The major components of airway mucus are heavily O-glycosylated mucin glycoproteins, divided into gel-forming mucins and transmembrane mucins. The gel-forming mucins MUC5AC and MUC5B are the primary structural components of airway mucus, and they enable efficient clearance of pathogens by mucociliary clearance. MUC5B is constitutively expressed in the healthy airway, whereas MUC5AC is upregulated in response to inflammatory challenge.

These glycoproteins crosslink via disulfide bonds and form longer branched structures (mucin multimers). Subsequently, the multimers can randomly undergo higher-order associations with glycoprotein chains and with small molecule proteins. These associations are driven by disulfide bridging, hydrophobic interactions, electrostatic forces, and hydrogen bonding, forming a three-dimensional viscoelastic biopolymeric network. This viscoelastic network is precisely what mucolytic agents are intended to disrupt or degrade.

Related Mucolytic Enzymes in the Scientific Literature

The scientific literature on mucolytic enzymes that are biochemically and functionally related to the claims made for Mucolase—and which appear alongside Mucolase in multi-enzyme formulations—includes:

• Serrapeptase (Serratiopeptidase): A proteolytic drug of natural origin, serratiopeptidase (SEPD), also known as Serratia E-15 protease or serralysin, serratiaprotease and serrapeptase. It is a serine protease (EC 3.4.24.40) derived from non-pathogenic enterobacteria existing in the intestine of the silkworm. The forms used in pharmaceutical preparations are isolated from Serratia marcescens or Serratia sp. E15 based on fermentation or recombinant production using Escherichia coli.
• Bromelain: A protease enzyme mixture extracted from the stems and fruit of the pineapple plant (Ananas comosus). The potency of bromelain supplements is measured in Gelatin Digesting Units (GDU) per gram; a 2400 GDU rating indicates a high-potency enzyme capable of digesting a substantial amount of protein.
• Microbial carbohydrate-active enzymes: Bacteria such as Akkermansia muciniphila reside in the mucosal layer of the large intestine and use the highly heterogeneous mucin glycoprotein as their main carbon source, employing an array of carbohydrate-active enzymes and sulfatases to access this complex energy source. Endo-acting enzymes from prominent mucin-degrading bacteria target the polyLacNAc structures within oligosaccharide side chains of both animal and human mucins. These O-glycanases are part of the large and diverse glycoside hydrolase 16 (GH16) family.

Proteases like serrapeptase, mucolase, and bromelain are described as decreasing the thickness of the mucus while at the same time increasing mucus production as well as dramatically increasing the transport of the mucus up the respiratory tract until it is either swallowed or eliminated from the body. In addition to enhancing the mechanical effects of mucus, proteases may enable special protective factors within mucus to more effectively neutralize invading organisms.

Common Forms and Preparations

In the supplement market, Mucolase as formulated by Enzymedica appears exclusively in oral capsule form, usually as part of a proprietary enzyme blend:

• In MucoStop formulations, Mucolase appears alongside amylase Thera-blend, hemicellulase, glucoamylase, invertase, cellulase Thera-blend, beta-glucanase, alpha-galactosidase, xylanase, pectinase (with phytase), protease Thera-blend, and lipase Thera-blend.
• In other Enzymedica immune-support products, Mucolase is combined with calcium, magnesium, protease Thera-blend, catalase, and serrapeptase, delivered in 100% vegetarian capsules of cellulose and water.
• Per serving of two capsules of MucoStop, the Mucolase component is listed at 60 mg in the enzyme blend targeting mucus proteins.
• Capsules are formulated as vegetarian/vegan, free of gluten, dairy, soy, eggs, nuts, wheat, and artificial additives.

MucoStop contains Thera-blend enzymes. Thera-blend is an exclusive process that combines multiple strains of enzymes that work at specific pH levels, resulting in superior performance in the body. Enzymes chosen for inclusion in such a blend are chosen to cover as many different target substrates as possible and to overlap with respect to temperature and pH profiles, such that the level of activity across a range of substrates and/or across a pH range is greater than the ranges for each enzyme alone.

Traditional and Historical Use

The term "Mucolase" as a named, isolated ingredient does not appear in historical or classical pharmacopeias, traditional Chinese medicine (TCM) herbals, Ayurvedic texts, European herbal monographs, or indigenous healing traditions. It is a 20th–21st century commercial enzyme designation, not a historically named botanical or natural product. No peer-reviewed historical scholarship documents "Mucolase" as a traditional preparation.

However, the broader category of mucolytic and mucoactive therapies—to which Mucolase belongs by function—does have historical roots. Serrapeptase, for example, has been used for decades in parts of Europe and Asia as an anti-inflammatory and mucolytic agent, especially after surgery or injury. In 1968, serrapeptase was introduced to the Japanese pharmaceutical market for a broad range of indications, including use as an anti-inflammatory agent for swelling due to surgery or trauma; for the treatment of chronic sinusitis and breast engorgement; as a mucolytic agent in patients with bronchitis, asthma, and tuberculosis; and for the clearing of bronchial secretions after surgery.

Proteolytic enzyme (PE) treatments were first popularized in Germany in the 1960s for inflammation, osteoarthritis, autoimmune diseases, and viral infections. The products usually contain a mixture of pancreatin, papain, bromelain, trypsin, and chymotrypsin.

The use of plant-based enzymes such as papain (from Carica papaya) and bromelain (from Ananas comosus) in food and folk medicine has older roots—papaya fruit has long been used in tropical cultures as a digestive aid and meat tenderizer, a use that reflects the activity of its cysteine protease content. However, the deliberate application of these enzymes in purified, standardized form to break down respiratory mucus is a modern pharmaceutical and nutraceutical development, and no direct historical lineage for "Mucolase" as a named ingredient can be established from authoritative historical sources.

Key Constituents and Active Compounds

The Mucolase Enzyme Itself

Mucolase is described as a high-potency proteolytic enzyme with mucolytic properties. The specific enzyme or enzyme blend that constitutes the proprietary "Mucolase" ingredient has not been disclosed in detail in the public domain or in peer-reviewed publications. Based on product literature, it functions as a proteolytic and/or glycan-cleaving enzyme that targets the protein backbone and glycan components of mucin glycoproteins.

Companion Enzymes in Mucolase-Containing Formulations

In the MucoStop formulation, Mucolase is accompanied by a range of other enzyme classes, each with defined biochemical activities relevant to mucus degradation:

• Protease (Thera-blend): Serine, cysteine, or metallo-proteases that cleave peptide bonds in mucin protein backbones.
• Amylase: Cleaves α-1,4-glycosidic bonds in polysaccharides; relevant to carbohydrate-rich components of mucus.
• Cellulase and Hemicellulase: Glycoside hydrolases targeting cellulosic polysaccharide linkages.
• Glucoamylase: Exo-acting enzyme releasing glucose from polysaccharide chains.
• Beta-glucanase: Targets β-1,3 and β-1,4-glucan linkages.
• Alpha-galactosidase: Cleaves terminal α-galactose residues; relevant to mucin O-glycan chains that may carry galactose moieties.
• Xylanase and Pectinase: Polysaccharide-degrading enzymes.
• Lipase: Targets the lipid components of biological secretions.

The additional protease, amylase, cellulase, lipase, and other enzymes in the blend are described as helping to process and break down associated compounds, which may support broader respiratory comfort and possibly assist with histamine-related mucus overproduction or seasonal allergy responses.

Mechanisms of Action

Proposed Mechanism of Mucolase

Mucolase is described as specifically designed to break down one compound—mucus—and is characterized as targeting and hydrolyzing excess mucus in the sinuses and nasal cavities, helping the body to naturally eliminate excess mucus, which may support immune health.

The proposed mechanism involves enzymatic hydrolysis of the glycoprotein components of mucus. Mucins are the dominant structural component of mucus; their degradation requires the coordinated action of multiple enzyme classes. Mucins are large glycoproteins whose degradation requires the expression of several glycosyl hydrolases to catalyze the cleavage of the oligosaccharide chains and release monosaccharides. Different groups of enzymes participate in the degradation of mucins. According to the currently accepted model, the structural processing of mucins is initiated by the action of peptidases that first cleave the non-glycosylated moieties of the protein backbone; followed by a series of α-glycoside hydrolases, which mainly remove the outermost glycan residues, such as GalNAc, Gal, and Fuc. The resulting oligosaccharides are converted to monosaccharides by the action of β-glycoside hydrolases, while additional peptidases can complete the hydrolysis of the mucin backbone.

By reducing the size and complexity of mucin polymers, mucolytic enzymes are theorized to reduce the viscoelastic properties of mucus—making it less thick and more easily cleared by the mucociliary apparatus. Airways obstruction with thick, adherent mucus is a pathophysiologic and clinical feature of muco-obstructive respiratory diseases. Mucins, the dominant biopolymer in mucus, organize into complex polymeric networks via the formation of covalent disulfide bonds, which govern the viscoelastic properties of the mucus gel.

pH-Range Activity (Thera-blend Technology)

Mucolase-containing formulations are described as being formulated to work across a broad pH range, thanks to proprietary Thera-blend enzyme technology, aiming for consistent effectiveness throughout the body. The resultant enzyme blend is characterized as having much higher utility than a single enzyme preparation, comprising a blend of two or more enzymes wherein the level of activity of the blend for a range of substrates is synergistically greater than that of each enzyme individually.

Systemic Absorption (Theoretical Basis)

A fundamental question for any orally administered enzyme supplement is whether the enzyme reaches the target tissue (e.g., the sinuses or airways) intact after passing through the gastrointestinal tract. Proteases like serrapeptase, mucolase, and bromelain are described as decreasing the thickness of mucus while increasing mucus transport up the respiratory tract. Whether orally ingested Mucolase achieves meaningful systemic concentrations in sinus or airway mucus has not been demonstrated in independently conducted, published clinical pharmacokinetic studies for this specific ingredient.

Scientific Evidence by Area of Use

No peer-reviewed clinical trials specifically testing the proprietary Mucolase enzyme ingredient (as sold by Enzymedica) in human subjects have been identified in PubMed, PMC, or other major databases at the time of writing. The following sections therefore present the human clinical evidence for closely related mucolytic enzymes—particularly serrapeptase (serratiopeptidase)—which are chemically and functionally analogous and appear alongside Mucolase in multi-enzyme formulations. Evidence pertaining to Mucolase specifically remains at the level of proposed mechanism and manufacturer claims.

Respiratory Health: Sinus Congestion and Mucus Reduction

This is the primary intended use of Mucolase-containing supplements. The clinical evidence for analogous mucolytic enzymes is mixed and limited in quality.

Five studies in otorhinolaryngology pathologies have explored the mucolytic properties of serratiopeptidase. Two were placebo-controlled trials, one of which showed serratiopeptidase reduced the severity of pain, amount, and purulence of secretions; in the second placebo-controlled study, outcomes were unclear. An open-label prospective study showed serratiopeptidase reduced the viscosity but not the elasticity of secretions in patients with chronic sinusitis. One study in chronic airway disease patients comparing serratiopeptidase with a non-treatment group concluded it reduced sputum viscosity, elasticity, and neutrophil count.

One research trial in Japan investigated the effect of serrapeptase on sputum properties and symptoms in patients with chronic airway diseases. After 4 weeks of serrapeptase treatment, sputum output, viscosity, and sputum neutrophil count decreased significantly. The frequency of coughing and expectoration also decreased. Another clinical study evaluated the effect of serrapeptase on the elasticity and viscosity of nasal mucus in adult patients with chronic sinusitis; serrapeptase was administered orally for 4 weeks, and dynamic viscosity at week 4 was significantly lower than at week 0.

In chronic respiratory conditions, some trials report improved sputum viscosity and ease of expectoration with serrapeptase, but others find no significant advantage over placebo.

Evidence Strength: For serrapeptase applied to mucus/sinusitis outcomes, evidence is preliminary and mixed. The studies that exist are generally small, some lack placebo controls, and they have not been replicated in large, double-blind RCTs with standardized outcome measures. For Mucolase (the proprietary ingredient) specifically, there are no independent clinical studies.

Post-Surgical Swelling and Inflammation

Serrapeptase often shows modest benefits in reducing swelling and improving mouth opening after dental and sinus surgeries. Effects on pain relief are inconsistent and generally weaker than standard drugs such as NSAIDs or corticosteroids.

In a randomized trial of subjects with moderate-to-severe knee osteoarthritis, oral proteolytic enzyme therapy had effectiveness comparable to diclofenac in relieving pain and increasing function.

Evidence Strength: Preliminary and inconsistent for serrapeptase and mixed proteolytic enzyme blends. No evidence specific to Mucolase.

Respiratory Diseases (COPD, Asthma, Bronchitis)

In 1968, serrapeptase was introduced to the Japanese pharmaceutical market for treatment of chronic sinusitis and as a mucolytic agent in patients with bronchitis, asthma, and tuberculosis, and for clearing bronchial secretions after surgery. A postmarketing study by Takeda Pharmaceuticals evaluated serrapeptase as a mucolytic agent in chronic bronchitis: a multicenter, double-blind, parallel-group trial in which 311 patients with difficulty expectorating were randomized to receive serrapeptase 10 mg three times daily after meals or placebo for 2 weeks.

Mucus-thinning, cough-inducing, and cough transport-facilitating drugs have been investigated in a large number of clinical studies for diverse indications such as bronchiectasis, COPD, acute and chronic bronchitis, and relief of acute cough from respiratory tract infections. However, many trials were open and non-controlled, and only relatively few randomised controlled trials are available for each individual drug in each indication.

Evidence Strength: Weak to preliminary for enzyme-based mucolytics in COPD and asthma. No direct evidence for Mucolase specifically. Broader mucolytic pharmacotherapy (e.g., N-acetylcysteine, carbocisteine) has stronger, though still limited, clinical evidence bases in these conditions.

Idiopathic Pulmonary Fibrosis

A randomized controlled trial examined Serracor-NK®, which contains the enteric-coated fibrinolytic enzymes serrapeptase and nattokinase and other proteolytic enzymes including bromelain, papain, lipase, rutin, amla, coenzyme Q10, and magnesium, along with Serra Rx260, a serrapeptase preparation, in patients with idiopathic pulmonary fibrosis. This is the most rigorous enzyme trial in a serious respiratory disease context identified, though the multi-ingredient formulation makes attribution of effects to any single enzyme impossible.

Digestive Wellness

When used in combination with other herbal or enzyme ingredients, Mucolase has been reported to improve the bioavailability of nutrients and the efficacy of herbal blends, owing to its ability to break down complex carbohydrates and proteins, supporting better nutrient absorption and overall gut health. These claims, however, come from manufacturer-adjacent sources rather than from independent peer-reviewed research. No clinical trial data on Mucolase or its formulations specifically addressing digestive outcomes has been identified in peer-reviewed literature.

Immune Support

In addition to enhancing the mechanical effects of mucus, proteases may enable special protective factors within mucus to more effectively neutralize invading organisms. Some of the protective factors secreted in mucus are secretory IgA, nitric oxide, lactoferrin, and various white blood cell-derived protease inhibitors that block viruses.

Preclinical studies indicate that proteolytic enzymes have immunomodulatory and tumoricidal properties. Such effects are thought to result from degradation of abnormal immune complexes. In clinical studies, oral administration of proteolytic enzymes to healthy volunteers resulted in immunomodulatory effects.

Evidence Strength: Preliminary, primarily preclinical for immune modulation by proteolytic enzyme blends. No clinical evidence specific to Mucolase.

Body Systems and Health Areas

Mucolase and the formulations in which it appears are associated primarily with the following body systems:

• Respiratory system: Upper and lower respiratory tract; sinuses, nasal cavities, bronchial airways. The primary claimed action is targeting and hydrolyzing excess mucus in the sinuses and nasal cavities.
• Immune system: Mucolytic activity is theorized to support mucosal immunity by facilitating clearance of pathogens trapped in mucus.
• Gastrointestinal system: When formulated with other digestive enzymes, the blend is associated with support of protein and carbohydrate digestion.
• Circulatory system (in products containing serrapeptase alongside Mucolase): The role of mucolytics has been suggested in protecting the body from respiratory pathogens ascribed to their expectorant action. Serrapeptase-associated fibrinolytic claims appear in formulations combining it with Mucolase, though these pertain to serrapeptase, not Mucolase specifically.

Dosage Forms and Reported Dosages

Dosages for Mucolase specifically, as reported in manufacturer product literature:

• Per serving of two capsules, the Mucolase component is listed at 60 mg in the enzyme blend.
• The recommended dose is 2 capsules three times daily on an empty stomach, preferably one hour before or two hours after a meal, with more taken as needed depending on the level of congestion.
• In some formulation variants, the dosing instruction is 1 capsule or as needed every 4–6 hours on an empty stomach.

For serrapeptase—a closely related and clinically studied mucolytic enzyme that frequently co-appears in the same formulations:

• The usual doses in the majority of human studies range from 10 to 60 mg/day in divided doses, with the most preferred dose of 10 mg thrice daily on an empty stomach, used for 2–4 weeks depending on the aim of therapy.
• The dose of 10 mg is considered equal to 20,000 units of enzyme activity.
• Doses in clinical trials range from 10 mg to 60 mg per day, with most effective protocols in the 20–40 mg range. Some high-potency products are labeled in serrapeptase activity units (SPU or SU) rather than milligrams, with approximately 40,000–120,000 SPU as an equivalent to the 10–30 mg mass range.
• In the Takeda postmarketing trial on chronic bronchitis, 311 patients received serrapeptase 10 mg three times daily after meals or placebo for 2 weeks.

Safety Considerations and Interactions

General Safety of Oral Proteolytic Enzyme Supplements

Proteolytic enzymes are possibly safe when taken appropriately. Side effects are usually mild or moderate and include stomach and intestinal complaints.

Proteolytic enzymes are made by animals, plants, fungi, and bacteria. They break down proteins in the body or on the skin, which might help with digestion or with the breakdown of proteins involved in swelling and pain. Some proteolytic enzymes that may be found in supplements include bromelain, chymotrypsin, ficin, papain, serrapeptase, and trypsin.

Known and Potential Interactions

Digestive enzymes generally do not pose the risk of severe interactions with other drugs. However, some interactions may be possible, including with warfarin (an anticoagulant), miglitol, and acarbose (alpha-glucosidase inhibitors used for diabetes). It is possible that taking these drugs with digestive enzymes may reduce the activity of the medications or enzymes.

The blood-thinning concern associated with proteolytic enzymes is real and should be respected—combining such enzymes with anticoagulants should be avoided or monitored carefully. This concern is specifically documented for serrapeptase and applies more broadly to mucolytic/proteolytic enzyme supplements.

Evidence is preliminary and limited by small sample sizes, varied dosing, and potential side effects such as gastrointestinal discomfort or increased bleeding risk.

Specific Serrapeptase Safety Data

Serratiopeptidase (a closely related mucolytic enzyme that appears alongside Mucolase in several formulations) is described as safe and effective, with fewer side effects than conventional mucolytics that may cause sedation, euphoria, gastrointestinal disturbances, respiratory irritation, and constipation.

Serrapeptase is generally well tolerated, but users may experience common mild side effects including gastrointestinal discomfort such as nausea and diarrhea, or rarely, skin rash or itching.

Enteric-coated serrapeptase is formulated with a pH-sensitive coating that dissolves only in the higher-pH environment of the small intestine, allowing the enzyme to survive and be absorbed intact. Nearly all of the clinical research showing systemic effects used enteric-coated formulations. Mucolase-containing products from Enzymedica use standard vegetarian capsules rather than enteric coating, which raises mechanistic questions about systemic delivery that have not been addressed in published research.

Pregnancy, Lactation, and Special Populations

Pregnant women can usually take digestive enzymes safely, but there has not been much research showing how digestive enzyme supplements affect breastfeeding. Use of digestive enzymes during pregnancy requires caution if the benefits outweigh the risks. Side effects during breastfeeding are unknown; caution is advised.

Allergenicity

Mucolase-containing products are generally labeled free of major allergens—gluten, dairy, soy, eggs, tree nuts, peanuts, wheat, and shellfish. However, individuals with known sensitivities to fungal or bacterial fermentation-derived enzymes should use caution, as the production organisms are not publicly disclosed for this proprietary ingredient.

Summary of Evidence Quality

Mucolase, as a proprietary enzyme ingredient, lacks independent peer-reviewed clinical trials evaluating its safety or efficacy in any health condition. The body of evidence relevant to its proposed mechanism of action derives from:

• Basic biochemistry of mucin structure and enzymatic mucin degradation (well-established in the scientific literature).
• Clinical trials of serrapeptase as a mucolytic agent—which show mixed, preliminary results for sinusitis and sputum viscosity reduction, with methodological limitations.
• Clinical research on mixed proteolytic enzyme blends—which shows modest and inconsistent benefits across inflammatory and post-surgical indications.
• Manufacturer product literature and retail-adjacent descriptions—which do not constitute independent evidence.

The overall evidence base for Mucolase-specific claims is insufficient to draw clinical conclusions. The ingredient may plausibly participate in mucolytic enzymatic activity based on the biochemical rationale, but this has not been demonstrated in human clinical trials that meet current standards of evidence-based medicine. Independent regulatory or institutional assessments (NIH ODS, NCCIH, EMA, EFSA, Cochrane) have not evaluated the proprietary Mucolase ingredient as a distinct entity.

References

• Cellular and Molecular Biology of Airway Mucins — PMC / NIH
• Mucus — PMC / NIH
• Defensive Properties of Mucin Glycoproteins during Respiratory Infections — PMC / NIH
• Respiratory Tract Mucin Genes and Mucin Glycoproteins in Health and Disease — Physiological Reviews
• Biopolymeric Mucin and Synthetic Polymer Analogs — PMC / NIH
• Carbohydrate-active enzymes from Akkermansia muciniphila break down mucin O-glycans to completion — Nature Microbiology
• Prominent members of the human gut microbiota express endo-acting O-glycanases to initiate mucin breakdown — Nature Communications
• Structural basis of mammalian mucin processing by OgpA from Akkermansia muciniphila — Nature Communications
• A family of di-glutamate mucin-degrading enzymes — Nature Catalysis
• Characterization of a highly conserved MUC5B-degrading protease MdpL from Limosilactobacillus fermentum — PMC
• Serratiopeptidase: A systematic review of the existing evidence — ScienceDirect (International Journal of Surgery)
• Serratiopeptidase, A Serine Protease Anti-Inflammatory, Fibrinolytic, and Mucolytic Drug — PMC / NIH
• Anti-Inflammatory and Anti-Oxidant Properties of N-Acetylcysteine: A Fresh Perspective — PMC / NIH
• Mucoactive Agents in the Therapy of Upper Respiratory Airways Infections — PMC / NIH
• Mucolytics for acute exacerbations of COPD: a meta-analysis — PMC / NIH
• An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases — American Journal of Respiratory and Critical Care Medicine
• A Randomized Controlled Trial of Systemic Enzyme Supplementation in Idiopathic Pulmonary Fibrosis — PMC / NIH
• Over-the-Counter Enzyme Supplements: What a Clinician Needs to Know — Mayo Clinic Proceedings
• Proteolytic Enzymes — Memorial Sloan Kettering Cancer Center Integrative Medicine
• Serrapeptase Uses, Benefits & Dosage — Drugs.com Natural Products Database
• MucoStop® Product Information — Enzymedica, Inc.
• Mucolase — Meteoric Biopharmaceuticals
• How Do Mucolytic Enzymes Work? — RxList
• Proteolytic Enzymes (Proteases) — WebMD Natural Medicines
• Compositions of beta-glucuronidase enzyme blends with enhanced enzymatic activity — US Patent 11807879